• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Clinical studies roundup: Scientists create functioning intestinal tissue from stem cells

Clinical studies roundup: Scientists create functioning intestinal tissue from stem cells

December 19, 2010 By MassDevice staff

Clinical trials roundup

Here’s a roundup of recent clinical trial and scientific study news:

  • Scientists create functioning intestinal tissue from stem cells
    For the first time, scientists have created functioning human intestinal tissue in the laboratory from pluripotent stem cells. In a study posted online Dec. 12 by Nature, scientists from Cincinnati Children’s Hospital Medical Center say their findings will open the door to unprecedented studies of human intestinal development, function and disease. The process is also a significant step toward generating intestinal tissue for transplantation, researchers say.
    Read more
  • Heart disease and stroke death rates declines over last 10 years
    The death rate from cardiovascular disease in the United States declined 28 percent since the late 1990s, but heart disease and stroke still account for one-third of all deaths, according to a new study in the American Heart Association journal Circulation, reports HealthDay.
    Read more
  • Benefits of pressure cycling technology cited in recent cancer and heart disease studies
    Pressure BioSciences Inc. (NSDQ:PBIO) announced that significant benefits were reported when the company’s, patented pressure cycling technology (PCT) platform was used in either the fixation or extraction of proteins from formalin-fixed, paraffin-embedded (FFPE) tissue samples in four recent cancer and heart disease studies.
    Read more
  • Vitamin K antagonists use for treatment of atrial fibrillation driven by availability of an oral formulation, cost and widespread inclusion on guidelines and formularies
    Arlington Medical Resources (AMR), a provider of market intelligence for the pharmaceutical and diagnostic imaging industries, finds that, in the treatment of atrial fibrillation, surveyed European cardiologists indicate that use of vitamin K antagonists, as a class, is primarily driven by the availability of an oral formulation, overall low cost and widespread inclusion on European medical society guidelines and hospital formularies. Vitamin K antagonists and low molecular weight heparins are the most commonly used anticoagulants across physician specialties in Europe.
    Read more
  • Canadian heart valve study provides evidence of On-X heart valve superior performance
    On-X Life Technologies Inc. (On-X LTI), announced the publication of results of a large, prospective multi-center Canadian trial with the On-X Prosthetic Heart Valve in the November issue of The Journal of Thoracic and Cardiovascular Surgery. According to the results of the report, “The On-X mechanical prosthesis provides favorable intermediate-term results with regard to major thromboembolism, hemorrhage and composites of valve-related complications.”
    Read more
  • Beaumont hospital launches atudy of single-dose radiation treatment for prostate cancer
    Beaumont Hospital radiation oncologists launched a research study to treat men with low to intermediate risk prostate cancer with a single dose of radiation. The study, approved by Beaumont’s Human Investigation Committee, builds upon 18 years of past research by Oakland University William Beaumont School of Medicine professor Dr. Alvaro Martinez and other Beaumont radiation oncologists on ways to kill cancer cells through powerful, targeted, short-term radiation treatment.
    Read more
  • Economic evaluation of FAME trial confirms using FFR in treatment of coronary artery disease is cost-effective
    St. Jude Medical Inc. (NYSE:STJ), a global medical device company, announced the publication of results from an economic evaluation of the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial, which confirmed FFR-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease improves patient outcomes and offers cost-saving benefits to the U.S. healthcare system.
    Read more
  • Study shows BSGI/MBI contributes significantly to patient management with its ability to detect breast cancer in difficult to diagnose patients
    Dr. Barbara Ward and others of Weinstein Imaging determined that Breast-Specific Gamma Imaging/Molecular Breast Imaging (BSGI/MBI) provides additional information when conventional imaging is indeterminate and greater confidence is required to improve diagnostic accuracy. The data from the retrospective study demonstrated that BSGI contributed significantly to patient management by detecting cancer in 7 of the 73 patients (9 percent), and was presented last week at the San Antonio Breast Cancer Symposium.
    Read more
  • Sequenom announces publication acceptance of manuscript from Trisomy 21 R&D verification study
    Sequenom Inc. (NSDQ:SQNM) today announced the acceptance of a manuscript describing results from the R&D “locked-assay” verification study conducted by the company’s wholly-owned subsidiary, Sequenom Center for Molecular Medicine.
    Read more
  • deCODE discovers genetic markers that improve the power of PSA testing for detecting prostate cancer

    Scientists from deCODE genetics and academic colleagues from Iceland, the U.K., U.S., Netherlands, Spain and Romania reported the discovery of a set of single-letter variations in the sequence of the human genome (SNPs) that impact individual baseline levels of prostate specific antigen, or PSA. A prostate biopsy is routinely recommended for men with PSA above a certain threshold. However, PSA levels can rise for reasons unrelated to prostate cancer and baseline healthy levels vary substantially between individuals, resulting in many men without cancer being biopsied while cancer in others is not detected. The paper published today demonstrates that analysis of four SNPs can be used to derive a personalized PSA threshold that more accurately identifies those men who are more likely to have a positive biopsy and for whom one should therefore be recommended.
    Read more
  • Study shows how flu infections may prevent asthma
    In a paper that suggests a new strategy to prevent asthma, scientists at Children’s Hospital Boston and their colleagues report that the influenza virus infection in young mice protected the mice as adults against the development of allergic asthma. The same protective effect was achieved by treating young mice with compound isolated from the bacterium Helicobacter pylori (H. pylori), a bacterium that colonizes the stomach and is best known for causing ulcers and increasing the risk of gastric cancers.
    Read more
  • New clinical study presented at the American Association of Respiratory Care finds Masimo Rainbow acoustic monitoring accurate for respiration rate assessment

    Masimo (NSDQ:MASI) announced today that a new clinical study demonstrating the accuracy of its latest medical technology breakthrough—Rainbow Acoustic Monitoring™—was presented last week at the American Association of Respiratory Care’s (AARC) 56th Annual International Respiratory Congress in Las Vegas. The largest gathering of respiratory care clinicians in the world, the AARC Annual Meeting provides an important platform for previewing the latest in medical developments and clinical research to respiratory care thought-leaders.
    Read more
  • Clinical investigators address confusion over study of patent foramen ovale in stroke patients

    W. L. Gore & Associates released the following statement from its REDUCE Clinical Study Principal Investigators on behalf of the Gore REDUCE Clinical Study Steering Committee in response to the recent CLOSURE I results presentation. The Gore REDUCE Clinical Study is a prospective, randomized, multi-center, multi-national trial designed to demonstrate safety and effectiveness of the GORE HELEX Septal Occluder for patent foramen ovale closure in patients with history of cryptogenic stroke or imaging-confirmed Transient Ischemic Attack (TIA). The unique study includes up to fifty investigational sites in the U.S. and Europe.
    Read more
  • Stimatix GI reports meeting primary endpoints in pre-clinical studies demonstrating effectiveness of the AOS-C1000(TM) colostomy management system

    Stimatix GI reported that the AOS-C1000(TM), a unique colostomy management device, met primary and secondary endpoints in pre-clinical in-vivo animal studies. The study was conducted under the direction of Dr. Ron Greenberg, Senior Surgeon, Department of Surgery, Sourasky Medical Center, Tel Aviv Israel. Primary endpoints of repeatable stoma sealing for continence control as well as secondary endpoints regarding tissue pathology and survival were met confirming the AOS-C1000(TM) as capable of enabling repeatable colostomy site (stoma) sealing for continence control.
    Read more
  • First patient enrolled in multi-center clinical trial of the CorMatrix ECM for pericardial closure to reduce the incidence of new onset postoperative atrial fibrillation
    CorMatrix Cardiovascular Inc., an Atlanta-based company dedicated to developing and delivering extracellular matrix (ECM) biomaterial devices that harness the body’s innate ability to repair damaged cardiovascular tissue, announced that Franciscan Alliance/St. Francis Heart Center in Indianapolis, Ind. is the first site to enroll a patient in the multi-center clinical trial of the CorMatrix ECM for Pericardial Closure to reduce the incidence of new onset postoperative atrial fibrillation.
    Read more

Filed Under: Business/Financial News, News Well Tagged With: Clinical Trials

In case you missed it

  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
  • FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths
  • Boston Scientific’s Acurate Neo2 valve performs well in studies
  • MicroTransponder reports first commercial implantation of its stroke rehab neurostim system
  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D
  • Abbott reports positive data on heart valve therapies
  • OncoRes Medical raises another $12.5M
  • NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia
  • Inogen appoints Agnes Lee as senior VP of investor relations, strategic planning
  • Google Health hires FDA’s chief digital health officer
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says

RSS From Medical Design & Outsourcing

  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]
  • How Minnetronix Medical helped Lazurite with its wireless surgical camera
    Minnetronix Medical (St. Paul, Minnesota) has played an important development and manufacturing partner role with Lazurite’s wireless surgical camera system. It’s been nearly two months since Lazurite (formerly Indago) announced FDA 510(k) clearance of its ArthroFree system. ArthroFree combines proprietary low-heat, high-intensity Meridiem light engine technology with advanced camera, battery and wireless transmission technologies and… […]
  • Instron releases TrendTracker data analysis workflow platform
    Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze… […]
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
    Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor’s North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world’s largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company’s largest business group. The… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS